Viewing Study NCT04499157


Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2025-12-29 @ 7:22 AM
Study NCT ID: NCT04499157
Status: UNKNOWN
Last Update Posted: 2023-02-08
First Post: 2020-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Sponsor: Centre Hospitalier Universitaire, Amiens
Organization:

Study Overview

Official Title: Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Status: UNKNOWN
Status Verified Date: 2023-02
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MEMO-GCAO
Brief Summary: Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients.

The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: